Brain Tumor Assessment: Integrating PET/Computed Tomography and MR Imaging Modalities.

Brain tumors; FAPI; FDG; FET; Neuro-oncology; Radiomics; Radiopharmaceuticals; Fluorodeoxyglucose F18; Humans; Multimodal Imaging/methods; Brain/diagnostic imaging; Positron-Emission Tomography/methods; Brain Neoplasms/diagnostic imaging; Magnetic Resonance Imaging/methods; Positron Emission Tomography Computed Tomography/methods; Radiation; Radiology, Nuclear Medicine and Imaging

Abstract :

[en] While MR imaging is the main imaging modality to assess brain tumors, PET imaging has a specific role. Among the many tracers that have been proposed and are still being developed, 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) and O-(2-[18F]-fluoroethyl)-l-tyrosine ([18F]FET) PET remain the most solidly established in the clinics. In particular, [18F]FET has gained increased acceptance due to its higher sensitivity. In this paper, we present an overview of the current clinical status of brain tumor imaging, with emphasis on PET imaging.

Disciplines :

Radiology, nuclear medicine & imaging

Author, co-author :

Steenhout, Camille ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco

Deprez, Louis ; Université de Liège - ULiège > Département des sciences cliniques

Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire

Withofs, Nadia ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie

Language :

English

Title :

Brain Tumor Assessment: Integrating PET/Computed Tomography and MR Imaging Modalities.

Publication date :

January 2025

Journal title :

PET Clinics

ISSN :

1556-8598

eISSN :

1879-9809

Publisher :

W.B. Saunders, United States

Volume :

Issue :

Pages :

165 - 174

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S1556859824000749?httpAccept=text/xml

Available on ORBi :

since 20 November 2024

Statistics

Number of views

42 (3 by ULiège)

Number of downloads

36 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Sung, H., Ferlay, J., Siegel, R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71:3 (2021), 209–249.
Singnurkar, A., Poon, R., Detsky, J., 18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis. J Neuro Oncol 161:1 (2023), 1–12.
McNeill, K.A., Epidemiology of brain tumors. Neurol Clin 34:4 (2016), 981–998.
Overcast, W.B., Davis, K.M., Ho, C.Y., et al. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Curr Oncol Rep, 23(3), 2021, 34.
Zhang, J., Traylor, K.S., Mountz, J.M., PET and SPECT imaging of brain tumors. Semin Ultrasound CT MRI 41:6 (2020), 530–540.
Louis, D.N., Perry, A., Wesseling, P., et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:8 (2021), 1231–1251.
Weller, M., Van Den Bent, M., Preusser, M., et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:3 (2021), 170–186.
Tsitsia, V., Svolou, P., Kapsalaki, E., et al. Multimodality-multiparametric brain tumors evaluation. Hell J Nucl Med. 20:1 (2017), 57–61.
Horowitz, T., Tabouret, E., Graillon, T., et al. Contribution of nuclear medicine to the diagnosis and management of primary brain tumours. Rev Neurol (Paris) 179:5 (2023), 394–404.
Withofs, N., Kumar, R., Alavi, A., et al. Facts and fictions about [18F]FDG versus other tracers in managing patients with brain tumors. Pet Clin 17:3 (2022), 327–342.
Li, Y., Ma, Y., Wu, Z., et al. Advanced imaging techniques for differentiating pseudoprogression and tumor recurrence after immunotherapy for glioblastoma. Front Immunol, 12, 2021, 790674.
Broen, M.P.G., Smits, M., Wijnenga, M.M.J., et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 20:10 (2018), 1393–1399.
Romano, A., Palizzi, S., Romano, A., et al. Diffusion weighted imaging in neuro-oncology: diagnosis, post-treatment changes, and advanced sequences—an updated review. Cancers, 15(3), 2023, 618.
Korfiatis, P., Erickson, B., The basics of diffusion and perfusion imaging in brain tumors. Appl Radiol, 2014, 22–29.
Pons-Escoda, A., Smits, M., Dynamic-susceptibility-contrast perfusion-weighted-imaging (DSC-PWI) in brain tumors: a brief up-to-date overview for clinical neuroradiologists. Eur Radiol 33:11 (2023), 8026–8030.
Weinberg, B.D., Kuruva, M., Shim, H., et al. Clinical applications of magnetic resonance spectroscopy in brain tumors. Radiol Clin North Am 59:3 (2021), 349–362.
Haacke, E.M., Mittal, S., Wu, Z., et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. Am J Neuroradiol 30:1 (2009), 19–30.
Mittal, S., Wu, Z., Neelavalli, J., et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. Am J Neuroradiol 30:2 (2009), 232–252.
Lingl, J.P., Wunderlich, A., Goerke, S., et al. The value of APTw CEST MRI in routine clinical assessment of human brain tumor patients at 3T. Diagnostics, 12(2), 2022, 490.
Blystad, I., Warntjes, J.B.M., Smedby, Ö., et al. Quantitative MRI using relaxometry in malignant gliomas detects contrast enhancement in peritumoral oedema. Sci Rep, 10(1), 2020, 17986.
Falk Delgado, A., De Luca, F., Van Westen, D., et al. Arterial spin labeling MR imaging for differentiation between high- and low-grade glioma—a meta-analysis. Neuro Oncol 20:11 (2018), 1450–1461.
Zhao, J., bin, Li J., yan, Wang J., et al. Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting IDH-1 gene mutation status. NeuroImage Clin 19 (2018), 174–181.
Miloushev, V.Z., Granlund, K.L., Boltyanskiy, R., et al. Metabolic imaging of the human brain with hyperpolarized 13c pyruvate demonstrates 13C lactate production in brain tumor patients. Cancer Res 78:14 (2018), 3755–3760.
Kilbourn, M.R., Small molecule PET tracers for transporter imaging. Semin Nucl Med 47:5 (2017), 536–552.
Law, I., Albert, N.L., Arbizu, J., et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 46:3 (2019), 540–557.
Delbeke, D., Meyerowitz, C., Lapidus, R.L., et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high grade brain tumors with PET. Radiology, 1995, 47–52.
Takahashi, M., Soma, T., Mukasa, A., et al. Pattern of FDG and MET distribution in high- and low-grade gliomas on PET images. Clin Nucl Med 44:4 (2019), 265–271.
Cecchin, D., Garibotto, V., Law, I., et al. PET imaging in neurodegeneration and neuro-oncology: variants and pitfalls. Semin Nucl Med 51:5 (2021), 408–418.
Chiang, G.C., Galla, N., Ferraro, R., et al. The added prognostic value of metabolic tumor size on FDG-PET at first suspected recurrence of glioblastoma multiforme. J Neuroimaging 27:2 (2017), 243–247.
McCullough, B.J., Ader, V., Aguedan, B., et al. Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling error. J Neuro Oncol 136:1 (2018), 181–188.
Ouyang, Z.Q., Zheng, G.R., Duan, X.R., et al. Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis. Quant Imaging Med Surg 13:8 (2023), 4943–4959.
Alshehri, S., Prior, J., Moshebah, M., et al. Negative 18F-FET PET/CT in brain metastasis recurrence: a teaching case report. Eur J Hybrid Imaging, 5(1), 2021, 21.
Schlürmann, T., Waschulzik, B., Combs, S., et al. Utility of amino acid PET in the differential diagnosis of recurrent brain metastases and treatment-related changes: a meta-analysis. J Nucl Med 64:5 (2023), 816–821.
De Zwart, P.L., Van Dijken, B.R.J., Holtman, G.A., et al. Diagnostic accuracy of PET tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and metaanalysis. J Nucl Med 61:4 (2020), 498–504.
Van Weehaeghe, D., Lapauw, B., Fraioli, F., et al. EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours. Eur J Nucl Med Mol Imag 51:8 (2024), 2367–2370.
Langen, K.J., Stoffels, G., Filss, C., et al. Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[ 18 F]fluoroethyl)- L -tyrosine (FET). Methods 130 (2017), 124–134.
Stegmayr, C., Stoffels, G., Filß, C., et al. Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology. Nucl Med Biol 92 (2021), 78–84.
Unterrainer, M., Galldiks, N., Suchorska, B., et al. 18 F-FET PET uptake characteristics in patients with newly diagnosed and untreated brain metastasis. J Nucl Med 58:4 (2017), 584–589.
Koh, E.S., Gan, H.K., Senko, C., et al. [ 18 F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. BMJ Open, 13(8), 2023, e071327.
Chen, H., Pang, Y., Wu, J., et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47:8 (2020), 1820–1832.
Mori, Y., Dendl, K., Cardinale, J., et al. Fapi PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology, 306(2), 2023, e220749.
Hotta, M., Rieger, A.C., Jafarvand, M.G., et al. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol, 96(1142), 2023, 20220463.
Röhrich, M., Loktev, A., Wefers, A.K., et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT. Eur J Nucl Med Mol Imag 46:12 (2019), 2569–2580.
Windisch, P., Röhrich, M., Regnery, S., et al. Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol 150 (2020), 159–163.
Castello, A., Albano, D., Muoio, B., et al. Diagnostic accuracy of PET with 18F-fluciclovine ([18f]FACBC) in detecting high-grade gliomas: a systematic review and meta-analysis. Diagnostics, 13(24), 2023, 3610.
Schuster, D.M., Nanni, C., Fanti, S., et al. Anti-1-Amino-3- 18 F-Fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med 55:12 (2014), 1986–1992.
Kumar, A., ArunRaj, S.T., Bhullar, K., et al. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo. Neuroradiology 64:5 (2022), 969–979.
Brighi, C., Puttick, S., Woods, A., et al. Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as imaging biomarkers in adult recurrent glioblastoma. Int J Mol Sci, 24(22), 2023, 16208.
Zoi, V., Giannakopoulou, M., Alexiou, G.A., et al. Nuclear medicine and cancer theragnostics: basic concepts. Diagnostics, 13(19), 2023, 3064.
Kumar, A., Ballal, S., Yadav, M.P., et al. 177Lu-/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept. Clin Nucl Med 45:12 (2020), e512–e513.
Yip, S.S.F., Aerts, H.J.W.L., Applications and limitations of radiomics. Phys Med Biol 61:13 (2016), R150–R166.
Alizadeh, M., Broomand Lomer, N., Azami, M., et al. Radiomics: the new promise for differentiating progression, recurrence, pseudoprogression, and radionecrosis in glioma and glioblastoma multiforme. Cancers, 15(18), 2023, 4429.
Piccardo, A., Albert, N.L., Borgwardt, L., et al. Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 49:11 (2022), 3852–3869.